Lawyers are predicting a spike in litigation after a new report from a federal agency.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic drugs, including significant price markups by PBMs for cancer, HIV, and a variety of other critical drugs.